Incentives to bring vaccines to market are shrinking. Drugmakers are scaling back research investments and cutting jobs.

Vinay Prasad to leave in April after decisions involving vaccine reviews and specialty drugs for rare diseases ...

Dr. Vinay Prasad drew criticism for overriding career scientists and rejecting drugs by companies seeking agency approval.

Moderna said it met with the FDA on Tuesday to discuss the vaccine and afterward, the U.S. regulator accepted a revised ...

Vinay Prasad’s exit — his second from the agency in less than a year — comes after sharp criticism of his handling of drug ...

Vinay Prasad, the top regulator overseeing vaccines and complex treatments for difficult diseases, had previously lost his job in July before getting it back less than two weeks later.

The Food and Drug Administration’s vaccine chief, Dr. Vinay Prasad, will depart the agency next month, an FDA spokesperson ...

Moderna said the Food and Drug Administration has agreed to review its experimental mRNA flu shot, reversing an earlier decision to refuse to accept the application. The FDA is slated to make a ...

The Food and Drug Administration's controversial vaccine chief, Dr. Vinay Prasad, is once again leaving the agency.

Microbial threats against human health are only growing. Luckily, researchers are developing new vaccines that are up to the challenge.

Moderna's shares close up 6% Moderna to conduct post-marketing study in older adults FDA decision expected by August 5 Feb 18 (Reuters) - Moderna said on Wednesday the U.S. Food and Drug ...

Add Yahoo as a preferred source to see more of our stories on Google. In December 2025, Moderna submitted an application to the FDA to approve the first mRNA-based flu vaccine. Catherine Falls ...